BRAF and melanoma: Analysis of subgroups from the different randomized trials appears to suggest that patients with BRAF-mutant melanoma, elevated LDH, mucosal melanoma, asymptomatic brain metastases, or PD-L1-negative status may obtain a greater benefit from the combination than from single-agent ipilimumab or anti-PD-1 monotherapies.